This inventor holds 1 USPTO granted patent. Top assignee: Aventis Pharma Deutschland, Gmbh. Active years: 2003.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2003
Title: The Innovative Path of Eric Ruuth in Pharmaceutical Advancements
Introduction
Eric Ruuth, an inventor based in Boulogne, France, has made significant contributions to the pharmaceutical field through his innovations. With one patent to his name, he has demonstrated the potential for advancements in drug formulation and processes, particularly in relation to L-dihydroorotic acid.
Latest Patents
Ruuth's notable patent details a "Process for obtaining L-dihydroorotic acid and use thereof." This invention describes a method utilizing chromatography on an anionic exchange material in a base water mixture under pressures ranging from approximately 1.1 MPa to 40 MPa. The innovative process has implications in investigating the in vitro and in vivo activity of various compounds, including N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide and N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrontonamide.
Career Highlights
Eric Ruuth works with Aventis Pharma Deutschland GmbH, a leader in the pharmaceutical industry. His career reflects a commitment to enhancing drug development through scientific research and novel approaches. The unique processes he has helped develop are indicative of the innovative culture at his workplace.
Collaborations
Throughout his career, Ruuth has collaborated with esteemed colleagues, including Ulrike Milbert and Robert R. Bartlett. These partnerships highlight the collaborative nature of innovation in the pharmaceutical sector, where diverse expertise comes together to tackle complex challenges in drug development.
Conclusion
Eric Ruuth's contributions to the field of pharmaceuticals through his patent for the process of obtaining L-dihydroorotic acid represent the spirit of innovation. As he continues his work at Aventis Pharma Deutschland GmbH, the impact of his inventions may lead to significant advancements in medical research and therapeutic applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
